Thyssenkrupp creates AI bot to optimize supply chain

“alfred” supports his colleagues by dynamically managing the global logistics network with 271 warehouse sites and more than 150,000 products and services.
Updated 17 June 2019

Thyssenkrupp creates AI bot to optimize supply chain

Thyssenkrupp Materials Services’ Microsoft-supported AI solution “alfred” has been integrated into the processes of the materials distribution and services provider.
“alfred” supports his colleagues by dynamically managing the global logistics network with 271 warehouse sites and more than 150,000 products and services.
As with his namesake — Alfred Krupp — “alfred” will help to optimize transport routes and thus save in the transport of thousands of tons of material per year.
In addition, materials will be available more quickly at the right locations in the future.
Klaus Keysberg, CEO of Thyssenkrupp Materials Services, said: “Artificial intelligence is one of the technologies that will make a decisive contribution to competitiveness in materials distribution in the future. With ‘alfred,’ we are taking an important step toward making our processes even more efficient and optimizing our value chain. At the same time, he gives us better insight into our customers’ needs so that we can align our offerings accordingly. In the medium term, this holistic approach will also open up new business opportunities for us.”


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.